BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | May 6, 2017
Product Development

Finding gems in India

For Agios Pharmaceuticals Inc. , the decision to license molecules from Indian CRO Aurigene Discovery Technologies Ltd. was a special case intended to save time getting a new project off the ground, rather than part of...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Cancer

...INDICATION: Breast cancer; colorectal cancer; melanoma Patient sample and mouse studies suggest CSN5 inhibitors, alone or...
...could help treat breast cancer, colorectal cancer and melanoma. In breast cancer patients, levels of CSN5...
...include identifying and testing small molecule inhibitors of CSN5. TARGET/MARKER/PATHWAY: COP9 signalsome complex subunit 5 (CSN5...
BioCentury | Nov 30, 2016
Distillery Therapeutics

Cancer

...INDICATION: Lymphoma; cancer In vitro , cell culture and mouse studies identified a tetrahydroimidazoazepinol-based CSN5 inhibitor...
...assays followed by chemical synthesis and optimization of hits identified a tetrahydroimidazoazepinol compound that inhibited CSN5...
...AG include making the compound available for academic collaboration. TARGET/MARKER/PATHWAY: COP9 signalsome complex subunit 5 (CSN5...
BioCentury | Apr 15, 2013
Strategy

IP armamentarium

...develop an RNAi therapeutic targeting WEE1 tyrosine kinase (WEE1) and COP9 signalsome complex subunit 5 (CSN5...
BioCentury | Apr 15, 2013
Finance

De-risking money

...proteins that also regulate protein homeostasis. The targets are COP9 signalosome complex subunit 5 ( CSN5...
BioCentury | Apr 10, 2013
Financial News

Cleave raises $10M in series A extension

...targets p97, while the company's other two programs target COP9 signalosome complex subunit 5 ( CSN5...
BioCentury | Mar 25, 2013
Emerging Company Profile

Cleave: Proteasome alternatives

...be more amenable to prolonged inhibition. Two of them, COP9 signalosome complex subunit 5 ( CSN5...
BioCentury | Jun 13, 2011
Company News

Alnylam, Tekmira deal

...subunit 5 ( CSN5 ; COPS5 ; JAB1 ). Tekmira is conducting preclinical testing on WEE1/CSN5...
BioCentury | Sep 15, 2008
Clinical News

Tekmira preclinical data

...Tekmira said the National Cancer Institute has presented data showing CSN5 3/8siRNA delivered using its SNALP...
...the International Liver Cancer Association meeting in Chicago. Tekmira Pharmaceuticals Corp. (TSX:TKM), Burnaby, B.C. Product: SNALP-CSN5...
Items per page:
1 - 10 of 12